Treatment of Acute Lymphoblastic Leukemia in Children.

Trial Profile

Treatment of Acute Lymphoblastic Leukemia in Children.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Pegaspargase (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexrazoxane; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Enzon Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 1 Jun 2015 to 1 Jun 2018.
    • 19 Jun 2017 Planned End Date changed from 1 Jun 2015 to 1 Jun 2018.
    • 05 Nov 2015 Status changed from active, no longer recruiting to completed, according to results published in Results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top